Novolog Mix is an insulin analog premix containing 30% rapid-acting insulin aspart and 70% that has been modified into a long-acting formulation. It has been approved in a subcutaneous injection formulation, for the control of hyperglycemia. Hyperglycemia is an abnormally increased content of sugar in the blood.
Diabetes is a chronic disease that requires a combination of professional medical care and self-management through strict attention to diet, self-medication, and frequent monitoring one's blood sugar level.
Approval of NovoLog Mix 70/30 is based on results from clinical trials evaluating glycaemic control in subjects with type 1 and 2 diabetes.
Adverse events associated with the use of human insulin therapy include (but are not limited to) the following:
NovoLog Mix 70/30 regulates glucose metabolism. Insulins, including Novolog Mix, bind to insulin receptors on muscle and fat cells. They lower blood glucose by facilitating the cellular uptake of glucose, while simultaneously inhibiting the output of glucose from the liver.
For additional information on Novolog Mix 70/30, please visit Novo Nordisk.
The Novolog Mix 70/30 drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.